EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Supernus Pharmaceuticals, Inc (0LB2) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Supernus Pharmaceuticals, Inc $22.93, price $42.36, upside -45.9%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

GB · ISIN US8684591089

SP Some data Sep 24, 2026

Supernus Pharmaceuticals, Inc

0LB2 · LSE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $22.93 · Strongly overvalued (−45.9%)
!Quality 58/100
!Mixed Growth (revenue 5y +6.7 %/yr)
!Loss-making · -3.7% net margin (TTM)
✓generates free cash flow
!Narrow moat 6/100
!Evidence only medium, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$56.26 $40.86 Fair Value $22.93 Dec 2025 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

10‑month range $40.86 – $56.26 · fair‑value band $14.34 – $39.75 · the $42.36 price screens above the $22.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

Show more

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Stock analysis

Supernus Pharmaceuticals, Inc (0LB2) currently trades at $42.36, while our model-based Fair Value estimate is $22.93, 45.9% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $24.91 per share, and 0 of the 11 models we run sit above the $42.36 price.

Bear case: the Asset-Based group reads lowest at $13.61, and 11 of the 11 models stay below the price. Evidence for this calculation is medium.

Scenario range: $14.34 (bear) to $39.75 (bull), the price of $42.36 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality).

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Supernus Pharmaceuticals, Inc reported revenue of $719M in FY2025 versus $580M in FY2021, a compound +5.5%/yr. Reported net income was −$38.6M in FY2025.

Key figures

Market cap $2.4B · P/E ratio 0.4 · EPS (TTM) $1.31 · Net margin −5.4% · Return on equity −2.8% · Return on assets (EBIT) 2.1% · Operating margin −3.6% · Revenue (TTM) $777M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

Fair Value models

Bear $14.34 Fair Value $22.93 Bull $39.75
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.9936 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $17.04 $24.91 $49.44 72
Growth DCF $16.15 $28.52 $48.45 71
5Y EBITDA Exit $14.16 $22.60 $39.12 68
All 11 models by family
DCF Models
FCF DCF $17.04 $24.91 $49.44 72
Owner Earnings $17.68 $36.20 $73.65 66
5Y Revenue Exit $12.96 $20.17 $35.23 66
5Y EBITDA Exit $14.16 $22.60 $39.12 68
10Y Revenue Exit $14.00 $26.65 $34.35 62
10Y EBITDA Exit $15.20 $29.18 $53.01 61
Multiples
EV/EBITDA $12.66 $16.07 $19.47 64
EV/Revenue $10.47 $13.90 $17.33 52
Asset-Based
NCAV (Graham) $10.16 $13.61 $20.32 51
Growth DCF
Growth DCF $16.15 $28.52 $48.45 71
Rev-Margin DCF $14.03 $22.73 $40.97 65

Open the full fair value analysis →

Notify me when 0LB2 reaches fair value

Put 0LB2 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 60 · Market factors (momentum, volatility) 39

Profitability 25
Margins and returns on capital today
Quality Growth 45
Are margins and returns improving?
Cashflow 57
Earnings quality: real cash, not paper profit
Fin. Strength 77
Balance sheet, leverage, solvency risk
Investment 90
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 19
Distance to the 52-week high (market factor)
Net Issuance 86
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 37/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Start year 2020 (pandemic). Over 10 years: +17.2% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
35.4% (2020) → −5.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+16.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +20.3% a year for the price and +13.4% for the forecasts.
Forecast 2026 (sales)+20.6%
Forecast 2027 (sales)+18.0%
Projected 2028 (sales)+16.0%
Projected 2029 (sales)+14.0%
Projected 2030 (sales)+12.0%

Watch 0LB2, get fair value alerts →

Compare Supernus Pharmaceuticals, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Supernus Pharmaceuticals, Inc · Fair Value
$22.93 −46%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Supernus Pharmaceuticals, Inc Fair Value". https://www.fairvalue-calculator.com/stock/0LB2

Frequently asked questions

Is Supernus Pharmaceuticals, Inc (0LB2) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $22.93 versus a price of $42.36, about −46% upside (overvalued).
What is the fair value of 0LB2?
Our model-based fair value for Supernus Pharmaceuticals, Inc is $22.93 (as of Sep 24, 2026), built from audited fundamentals. The current price: $42.36.
What is the quality score of 0LB2?
Supernus Pharmaceuticals, Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Supernus Pharmaceuticals, Inc (0LB2)?
Our model-based price target is the fair value of $22.93 (as of Sep 24, 2026) from 11 valuation models. Cautious scenario $14.34, optimistic scenario $39.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Supernus Pharmaceuticals, Inc stock forecast for 2026?
Our models put fair value at $22.93, about −46% upside versus a price of $42.36 (overvalued). Cautious scenario $14.34, optimistic scenario $39.75. The calculation is refreshed regularly with new filings.
What is the revenue of Supernus Pharmaceuticals, Inc (0LB2)?
Supernus Pharmaceuticals, Inc reported trailing-twelve-month revenue of about $777M (latest available figure, as of Sep 24, 2026).
What growth is priced into Supernus Pharmaceuticals, Inc (0LB2)?
For today's price to be fair in a discounted-cash-flow model, Supernus Pharmaceuticals, Inc would have to grow free cash flow by +23.2 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0LB2 use?
Our models discount Supernus Pharmaceuticals, Inc at 9.1 %: a base by market capitalisation (unknown), damped by beta 0.54, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Supernus Pharmaceuticals, Inc that is +23.2 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Supernus Pharmaceuticals, Inc (0LB2) delivered so far?
Over the past 5 years revenue at Supernus Pharmaceuticals, Inc grew +6.7 % a year. The price currently implies +23.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of Supernus Pharmaceuticals, Inc (0LB2)?
The free-cash-flow yield on the price is 1.92 %: that much free cash flow Supernus Pharmaceuticals, Inc produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Supernus Pharmaceuticals, Inc (0LB2)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Supernus Pharmaceuticals, Inc it is $22.93 per share (as of Sep 24, 2026), against a price of $42.36. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Supernus Pharmaceuticals, Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0LB2 trades above its calculated fair value: price $42.36, fair value $22.93, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0LB2?
No. The price is what the market pays today ($42.36); the fair value is what the company's own numbers justify ($22.93). For Supernus Pharmaceuticals, Inc the two are $19.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Supernus Pharmaceuticals, Inc worth?
The market values Supernus Pharmaceuticals, Inc at about $2.4B (market capitalisation, as of Sep 24, 2026). Per share that is $42.36; our models calculate a fair value of $22.93 per share.
What do the bullish and bearish scenarios say about 0LB2?
Our models span a range for Supernus Pharmaceuticals, Inc: cautious scenario $14.34, base $22.93, optimistic $39.75 per share (as of Sep 24, 2026, price $42.36). The range comes from different growth and margin assumptions, not from analyst opinions.
Is Supernus Pharmaceuticals, Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $42.36, calculated fair value $22.93 (−46%), Quality Score 58/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0LB2 calculated?
We run Supernus Pharmaceuticals, Inc through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $22.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Supernus Pharmaceuticals, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Supernus Pharmaceuticals, Inc (0LB2)?
The closing price on Oct 2, 2026 was $42.36. Our model-based fair value is $22.93, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Supernus Pharmaceuticals, Inc right now?
The price sits above even our optimistic bull case ($39.75). The favourable scenario is already priced in. The model range is unusually wide ($14.34 to $39.75). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Supernus Pharmaceuticals, Inc

How large is the market capitalisation of Supernus Pharmaceuticals, Inc (0LB2)?
The market capitalisation of Supernus Pharmaceuticals, Inc is $2.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Supernus Pharmaceuticals, Inc (0LB2)?
The price-to-earnings ratio of Supernus Pharmaceuticals, Inc is 0.4 (as of Jul 26, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What are the earnings per share of Supernus Pharmaceuticals, Inc (0LB2)?
Earnings per share at Supernus Pharmaceuticals, Inc are $1.31 (price ÷ EPS = P/E 0.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Supernus Pharmaceuticals, Inc (0LB2)?
The net margin of Supernus Pharmaceuticals, Inc is −5.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Supernus Pharmaceuticals, Inc (0LB2)?
The return on equity (ROE) of Supernus Pharmaceuticals, Inc is −2.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Supernus Pharmaceuticals, Inc (0LB2)?
On an EBIT basis the return on assets of Supernus Pharmaceuticals, Inc is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Supernus Pharmaceuticals, Inc (0LB2)?
The operating margin of Supernus Pharmaceuticals, Inc is −3.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Supernus Pharmaceuticals, Inc (0LB2)?
Revenue at Supernus Pharmaceuticals, Inc is growing +38.6% versus a year earlier (3y avg +2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Supernus Pharmaceuticals, Inc (0LB2) hold?
Supernus Pharmaceuticals, Inc holds more cash than debt, $67.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.